Cetrotide acetate
PreclinicalSmall molecule
Cetrotide acetate is one of 7 small molecule programs targeting Ovarian Hyperstimulation Syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Ovarian Hyperstimulation Syndrome
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Trelstar
OOncoVerity, Inc.
Approved
Prometrium
FerringApproved
Hcg
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Calcium Intravenous Infsuion
MMansoura University
Preclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Cetrotide acetate
VVirginia Center for Reproductive Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cetrotide acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details